Catalyst Wire Dossier Catalyst Wire Dossier

busulfan, cyclophosphamide, and antithymocyte globulin followed by stem cell transplant

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for busulfan, cyclophosphamide, and antithymocyte globulin followed by stem cell transplant, covering 2018-04-03 to 2018-04-03. Get the full timeline:

Most recent: Clinical Trial Update: Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer [Phase 2]

See pricing